Komori
Business alliance4272NIPPON KAYAKU CO.,LTD.Materials and Chemicals

Agreement Executed for the Transfer of Manufacturing and Marketing Approval for “ZOLADEX 3.6 mg Depot/LA 10.8 mg Depot”

Nippon Kayaku Co., Ltd. has entered into an agreement to assume the marketing authorizations for ZOLADEX® 3.6 mg Depot / LA 10.8 mg Depot, which AstraZeneca K.K. manufactures and markets in Japan. The timing of the transfer of the marketing authorizations has not yet been determined.

Worth reading
32Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Agreement concerning the transfer of marketing authorizations
4272NIPPON KAYAKU CO.,LTD.
Alliance partnerAstraZeneca K.K.
Details of the alliance
  1. 1

    Transfer of the marketing authorizations in Japan

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionManufacture and marketing of the product
LocationOsaka City, Osaka Prefecture
Impact on Business Performance

This will not affect the earnings forecast for the current fiscal year. If a long-term impact is expected depending on the future performance of the agreement, market conditions or other factors, the company will make a timely disclosure separately.

Contract Date25 May 2026
Agreements reached under this partnership
ItemDetails
Name of alliance partnerAstraZeneca K.K.
Alliance partner's business activitiesManufacture and marketing of the product
Alliance partner's locationOsaka City, Osaka Prefecture
Type of allianceAgreement concerning the transfer of marketing authorizations
Details of the allianceTransfer of the marketing authorizations in Japan
Contract Date25 May 2026
Impact on Business PerformanceThis will not affect the earnings forecast for the current fiscal year. If a long-term impact is expected depending on the future performance of the agreement, market conditions or other factors, the company will make a timely disclosure separately.
Items this document does not state (16)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Nippon Kayaku Co., Ltd. will assume responsibility for the product in order to optimize its life cycle and maintain and secure a stable, long-term supply system.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Agreement Executed for the Transfer of Manufacturing and Marketing Approval for “ZOLADEX 3.6 mg Depot/LA 10.8 mg Depot” | NIPPON KAYAKU CO.,LTD. (4272) timely disclosure | Komori